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INTRODUCTION
  Hypophosphatasia is a rare inherited bone disease resulting from 
mutations in the gene encoding tissue-nonspecific alkaline 
phosphatase (TNSALP), an enzyme predominant in skeleton,  
liver, kidney and teeth. 
  Diminished TNSALP activity causes accumulation of substrates 
that inhibit bone mineralization resulting in debilitating pain, 
fractures and low alkaline phosphatase (ALP) levels. 
  In 2015 the FDA approved asfotase alfa, a bone-targeted 
recombinant TNSALP, for treatment of infant/child onset 
hypophosphatasia.
  We present a case of hypophosphatasia treated with asfotase  
alfa resulting in improvements in whole body scan and pedometer 
step counts.
CASE REPORT
  In 2014, a 52-year-old female with chronic pain presented with 
over 30 years of bony pain, poor balance, falls, fractures and life-
long dental disease. 
  Physical exam displayed tenderness of long bones and waddling gait. 
  Blood work was remarkable for low ALP and low bone-specific 
ALP. Vitamin B6 level was significantly elevated. Calcium level 
was normal. Serum phosphorus was elevated. Intact parathyroid 
hormone level was elevated, with known diagnosis of chronic 
kidney disease, GFR 27 mL/min. Her 24-hour urine calcium, 
serum protein electrophoresis, celiac test, thyroid studies and 
vitamin D level were normal. N-telopeptide was elevated. 
  SPECT whole body scan demonstrated increased uptake with 
multiple fractures of the axial skeleton and proximal femurs; 
consistent with oncogenic osteomalacia. 
2014 WHOLE BODY BONE SCAN
 
IMPRESSION:
Extra-axial hyperdense lesion in left frontal region of the calvarium. Multiple 
fractures and focal areas of increased uptake in the axial skeleton as well as 
fractures of the proximal third of both femurs.
2017 WHOLE BODY BONE SCAN
IMPRESSION:
Minimal to mild focal activity at posterior right 10th and 11th rib, proximal left 
femur, vertex of skull, and right femur.
CONCLUSION
  This case highlights clinical proof of improvement after treatment 
with asfotase alfa based on increased daily step count and healing 
fractures on whole body scans. 
  Asfotase alfa is a newly approved therapy for hypophosphatasia and 
therefore long-term outcomes are not yet available, however short 
term patient reported subjective findings and clinical data are 
reassuring for successful treatment.
  Fibroblast growth factor 23 and indium 111 octreotide scan 
showed no evidence of malignancy. 
  DEXA scan showed osteopenia of the hip and forearm. 
  She was diagnosed with hypophosphatasia. 
  Initially, due to lack of options, she was treated with denosumab. 
After three injections, she developed a new atypical femur 
fracture requiring surgical rod placement; denosumab was 
discontinued. 
  In 2017, she was started on asfotase alfa with significant 
improvements in balance, endurance, and bone pain. 
  Prior to treatment, the patient required narcotic oral pain 
medicine, fentanyl patch and an assistive device to walk 3000 
steps daily; after treatment, she is walking over 10,000 steps 
daily without any pain pharmacotherapy. 
  Repeat whole body scan showed less focal uptake overall, 
consistent with healing fractures. 
TABLE 1.
Test Result Normal Value
Alkaline Phosphatase 11 U/L 35-120 U/L
Bone-Specific Alkaline Phosphatase 3 ug/L 7.0-22.4 ug/L
Vitamin B6 >2000 nmol/L 20.0-125.0 nmol/L
Calcium 9.8 mg/dL 8.5-10.1 mg/dL
Phosphorus 5.2 mg/dL 2.3-4.6 mg/dL
Intact Parathyroid Hormone 114.1 pg/mL 18.5-88.0 pg/mL
Parathyroid Hormone Related Peptide 3.4 pmol/L 0.0-3.4 pmol/L
Thyroid stimulating hormone 1.83 ulU/mL 0.35-4.00 ulL/mL
25-OH Vitamin D 42 ng/mL 30-100 ng/mL
N-Telopeptide 25.9 nM 6.2 to 19.0 nM
